ACCENTIA BIOPHARMACEUTICALS SIGNS EXCLUSIVE WORLDWIDE LICENSE FOR ALL NON-PRESCRIPTION INTRANASAL FORMULATIONS FOR SYMPTOMS ASSOCIATED WITH CHRONIC SINUSITIS

Accentia Biopharmaceuticals, Inc., has signed an amendment to its license with the Mayo Foundation for Medical Research and Education (Mayo Clinic). This amendment grants Accentia an exclusive worldwide license to all non-prescription (over-the-counter -- OTC) products that are intended to treat symptoms associated with chronic sinusitis (CS) by suppressing non-invasive (so-called "saprophytic") fungi in the mucus of patients. The amendment also grants Accentia the right to proceed with commercialization of a first product. BioSpace (http://home.businesswire.com/portal/site/biospace/index.jsp?epi-content=GENERIC&newsId=20060828005348&ndmHsc=v2*A1156158000000*B1156803784000*DgroupByDate*J2*N1003674&newsLang=en&beanID=1121007625&viewID=news_view)